NeuroSense Therapeutics Ltd.

Ticker: 1875091

Overview P/L Share Hold

Shareholding

Pattern breakdown

P/L Trends

(in millions)

RevenueExpenditureNet Profit

The ledger is blank.

Price Chart

Latest News

Regulatory2d ago, 6:41 pm

NeuroSense meets Health Canada on PrimeC ALS regulatory pathway

NeuroSense Therapeutics Ltd. announced a constructive meeting with Health Canada concerning the regulatory pathways for PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). The company presented additional data to support a New Drug Submission (NDS), focusing on its proposed NDS strategy and supporting clinical, biomarker, and long-term outcome data. An official response from Health Canada is anticipated in the third quarter of this year.

8 Jun 2026, 06:41 pm

Investment29 Apr, 1:19 am

NRSN Announces Pricing of Insider-Led PIPE Financing

NeuroSense Therapeutics Ltd. announced the pricing of an insider-led Private Investment in Public Equity (PIPE) financing. This development was communicated via a press release issued on April 28, 2026, which is included as Exhibit 99.1 in the company's Form 6-K filing.

29 Apr 2026, 01:19 am

Management Change26 Apr, 2:55 pm

NRSN CMO Dr. Ferenc Tracik to Step Down, Remain Advisor

NeuroSense Therapeutics Ltd. announced that Dr. Ferenc Tracik will step down from his role as Chief Medical Officer, effective April 27, 2026. Dr. Tracik will continue to support the Company as an independent advisor, providing strategic medical guidance on the PrimeC program. His departure is not a result of any disagreement with the Company.

26 Apr 2026, 02:55 pm

Corporate Events

No corporate events found.

Corporate Events

No corporate events found.